Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Mayo clinic hunts for blood test to spot throat cancer early

NCT ID NCT06356272

First seen Nov 06, 2025 · Last updated Jun 18, 2026 · Updated 40 times

Summary

This study looks for biological markers (biomarkers) in blood, tissue, and saliva that can show when HPV-related throat cancer is present or gone. Researchers will compare samples from 560 people with and without the cancer. The goal is to improve how doctors diagnose and track the disease, not to test a new treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLINICAL STAGE III HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Mayo Clinic in Rochester

    RECRUITING

    Rochester, Minnesota, 55905, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

The condition(s) this trial relates to.

carcinoma head and neck carcinoma head and neck neoplasm Head and Neck Neoplasms human papillomavirus-related squamous cell carcinoma oropharyngeal carcinoma oropharynx cancer oropharynx squamous cell carcinoma salivary gland cancer Squamous Cell Carcinoma of Head and Neck thyroid cancer Thyroid Neoplasms tumor of salivary gland

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.